AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17161948 — intervention group
Group type: COMPARATOR
Intervention: Balance tasks (easy and difficult)
Number of subjects: 0
Study 14735556 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 MHz cellular phone exposure (2 W)
Number of subjects: 32
Study 14735556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 MHz cellular phone exposure (1 W)
Number of subjects: 32
Study 14735556 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 32
Study 10983642 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV + 3TC + indinavir (IDV)
Number of subjects: 0
Study 10983642 — intervention group
Group type: COMPARATOR
Intervention: ZDV + delavirdine (DLV) + indinavir (IDV)
Number of subjects: 0
Study 8696355 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF) combined with pelvic floor muscle training (PFMT)
Number of subjects: 40
Study 8696355 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) alone
Number of subjects: 40
Study 1553169 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceed(TC7)
Number of subjects: 63
Study 3892184 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance cycle intervention
Number of subjects: 16
Study 3892184 — intervention group
Group type: COMPARATOR
Intervention: Control tasks (blinded)
Number of subjects: 16
Study 30574797 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg via 2-min injection (9 ml/min)
Number of subjects: 74
Study 30574797 — intervention group
Group type: EXPERIMENTAL
Intervention: HTX-019 130 mg via 30-min infusion (296 ml/h)
Number of subjects: 74
Study 30574797 — intervention group
Group type: COMPARATOR
Intervention: HTX-019 130 mg via injection
Number of subjects: 74
Study 30574797 — intervention group
Group type: COMPARATOR
Intervention: HTX-019 130 mg via infusion
Number of subjects: 74
Study 28012197 — intervention group
Group type: EXPERIMENTAL
Intervention: Light split into 5 fractions
Number of subjects: 39
Study 28012197 — intervention group
Group type: EXPERIMENTAL
Intervention: Light split into 2 fractions
Number of subjects: 39
Study 28012197 — intervention group
Group type: COMPARATOR
Intervention: Without light
Number of subjects: 39
Study 27702399 — intervention group
Group type: EXPERIMENTAL
Intervention: Work anxiety-coping group
Number of subjects: 123
Study 27702399 — intervention group
Group type: COMPARATOR
Intervention: Recreational group
Number of subjects: 123
Study 24888810 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab (20 mg/kg) plus paclitaxel (200 mg/m(2)) and carboplatin (AUC 6 mg · min/mL)
Number of subjects: 671
Study 24888810 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin alone
Number of subjects: 671
Study 23082142 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists
Number of subjects: 0
Study 23082142 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 0
Study 23082142 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists and GnRH antagonists
Number of subjects: 0
Study 19923505 — intervention group
Group type: COMPARATOR
Intervention: Morphine IV 20 microg x kg(‐1) x h(‐1)
Number of subjects: 30
Study 19923505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.1 mL x kg(‐1) x h(‐1) via FIC catheter
Number of subjects: 30
Study 19923505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 30
Study 19923505 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 30
Study 17691875 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-delivered tailored intervention
Number of subjects: 139
Study 17691875 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 139
Study 14985991 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (n=8)
Number of subjects: 16
Study 14985991 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study 12730354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynorphin A1‐13 (120 microg/kg)
Number of subjects: 23
Study 12730354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynorphin A1‐13 (500 microg/kg)
Number of subjects: 23
Study 12730354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10215751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 0.6 IU
Number of subjects: 28
Study 10215751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.2 IU
Number of subjects: 28
Study 10215751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH) at a dose of 1.8 IU
Number of subjects: 28
Study 10215751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of recombinant human growth hormone (rhGH) at a dose of 1 IU
Number of subjects: 28
Study 10215751 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of recombinant human growth hormone (rhGH)
Number of subjects: 28
Study 10215751 — intervention group
Group type: COMPARATOR
Intervention: Physiological GH profile in healthy females
Number of subjects: 28
Study 8932510 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 118
Study 1881996 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg gum)
Number of subjects: 10
Study 1881996 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg capsule)
Number of subjects: 10
Study 1881996 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (30 g)
Number of subjects: 10
Study 1881996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for nicotine)
Number of subjects: 10
Study 1881996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for caffeine)
Number of subjects: 10
Study 1881996 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for alcohol)
Number of subjects: 10
Study 6219455 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (oral administration)
Number of subjects: 34
Study 6219455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (oral administration)
Number of subjects: 34
Study 6219455 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy without additional therapy (observation)
Number of subjects: 34
Study 3873813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix
Number of subjects: 50
Study 3873813 — intervention group
Group type: COMPARATOR
Intervention: Hexabrix-20
Number of subjects: 50
Study 30201054 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive of €30 a month for 12 months for medication adherence.
Number of subjects: 133
Study 30201054 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 133
Study 26612093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CEF)
Number of subjects: 40
Study 26612093 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (PIP-TAZO)
Number of subjects: 40
Study 25266289 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV)
Number of subjects: 266
Study 25266289 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 100 mg arm
Number of subjects: 266
Study 25266289 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172
Number of subjects: 266
Study 25266289 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-5172 200 mg group
Number of subjects: 266
Study 24231014 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early enteral nutrition (nasojejunal feeding starting within four hours after admission)
Number of subjects: 101
Study 24231014 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (three standard hospital meals per os after the first wound dressing)
Number of subjects: 101
Study 20473064 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose olanzapine (1 mg/d)
Number of subjects: 422
Study 20473064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 20473064 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (haloperidol 10-20 mg/d or medium-high dose olanzapine 7.5-17.5 mg/d)
Number of subjects: 422
Study 19267094 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking prevalence among individuals aged 15-24 years
Number of subjects: 3057
Study 19267094 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking prevalence
Number of subjects: 3057
Study 19267094 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to quit smoking
Number of subjects: 3057
Study 19267094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trends in smoking prevalence
Number of subjects: 3057
Study 15667369 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-task exercise program (function group, n=33)
Number of subjects: 98
Study 15667369 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program (resistance group, n=34)
Number of subjects: 98
Study 15667369 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 98
Study 12743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (n=51)
Number of subjects: 51
Study 12743537 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=28)
Number of subjects: 51
Study 12743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with peripheral neuropathy (group B, n=13)
Number of subjects: 51
Study 12743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy (group C, n=13)
Number of subjects: 51
Study 12743537 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients without neuropathy (group A, n=18)
Number of subjects: 51
Study 10725526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol levels in patients with a history of aggression
Number of subjects: 38
Study 10725526 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol levels
Number of subjects: 38
Study 8863773 — intervention group
Group type: EXPERIMENTAL
Intervention: AS-1 RBCs stored for ≤ 42 days
Number of subjects: 0
Study 8863773 — intervention group
Group type: COMPARATOR
Intervention: CPDA-1 RBCs stored for ≤ 7 days
Number of subjects: 0
Study 1736342 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (Hemoccult‐II performed at least once)
Number of subjects: 61938
Study 1736342 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to screening
Number of subjects: 61938
Study 1736342 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Hemoccult‐II
Number of subjects: 61938
Study 1736342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61938
Study 6476835 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (NK 171) intravenously at a dose of 100‐130 mg/m2/day for five days
Number of subjects: 17
Study 6476835 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (NK 171) orally at a dose of 130‐170 mg/m2/day for five days
Number of subjects: 17
Study 30730931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care recommendations adherence
Number of subjects: 310
Study 30730931 — intervention group
Group type: EXPERIMENTAL
Intervention: Being male
Number of subjects: 310
Study 30730931 — intervention group
Group type: EXPERIMENTAL
Intervention: Good level of heart failure knowledge
Number of subjects: 310
Study 30730931 — intervention group
Group type: EXPERIMENTAL
Intervention: Free from chronic comorbid diseases
Number of subjects: 310
Study 30256551 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized adherence enhancement (CAE)
Number of subjects: 184
Study 30256551 — intervention group
Group type: COMPARATOR
Intervention: Bipolar-specific educational program (EDU)
Number of subjects: 184
Study 25772003 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback intervention
Number of subjects: 10
Study 25293882 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan FCT™ (extended-release niacin)
Number of subjects: 20
Study 25293882 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone
Number of subjects: 20
Study 22887972 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule developed from the derivation set
Number of subjects: 3459
Study 19933747 — intervention group
Group type: EXPERIMENTAL
Intervention: 700/400 kappa, rate responsive pacemaker
Number of subjects: 141
Study 19933747 — intervention group
Group type: COMPARATOR
Intervention: Implantable loop recorder (Medtronic Reveal thera RDR)
Number of subjects: 141
Study 17388753 — intervention group
Group type: EXPERIMENTAL
Intervention: Novolizer (PIF‐N)
Number of subjects: 46
Study 17388753 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler (PIF‐T)
Number of subjects: 46
Study 17388753 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Novolizer and Turbuhaler
Number of subjects: 46
Study 17388753 — intervention group
Group type: COMPARATOR
Intervention: Novolizer (PIF‐N) vs Turbuhaler (PIF‐T)
Number of subjects: 46
Study 16142294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell therapy (cell suspension from immature nervous and hemopoietic tissues)
Number of subjects: 10
Study 16142294 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically comparable)
Number of subjects: 10
Study 11865831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 40
Study 11865831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9797089 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstained from alcohol and consumed less than one cup of coffee or its equivalent per day
Number of subjects: 124
Study 9797089 — intervention group
Group type: COMPARATOR
Intervention: Consumed any alcohol and more than one cup of coffee per day
Number of subjects: 124
Study 7650184 — intervention group
Group type: EXPERIMENTAL
Intervention: BioStar Strep A OIA optical immune assay
Number of subjects: 500
Study 7650184 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott TestPack Plus Strep A
Number of subjects: 500
Study 7650184 — intervention group
Group type: COMPARATOR
Intervention: Culture with selective media
Number of subjects: 500
Study 2814944 — intervention group
Group type: EXPERIMENTAL
Intervention: Co‐dergocrine mesylate (Hydergine)
Number of subjects: 18
Study 2814944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 857691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 vol.% enflurane (group I)
Number of subjects: 22
Study 857691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 and 0.8 vol.% enflurane (group II)
Number of subjects: 22
Study 857691 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study 30414855 — intervention group
Group type: EXPERIMENTAL
Intervention: ZPL-3893787 (30 mg once-daily oral therapy)
Number of subjects: 98
Study 30414855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 29284500 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 50
Study 29284500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29284500 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 50
Study 27176144 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (167 mmol/day) for 3 weeks
Number of subjects: 35
Study 27176144 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (57 mmol/day) for 3 weeks
Number of subjects: 35
Study 27176144 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (167 mmol/day)
Number of subjects: 35
Study 27176144 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (57 mmol/day)
Number of subjects: 35
Study 24331269 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual hyoscyamine sulfate
Number of subjects: 92
Study 21815451 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mono‐pigtail stent (Group 1, n=65)
Number of subjects: 130
Study 21815451 — intervention group
Group type: COMPARATOR
Intervention: Standard double‐pigtail stent (Group 2, n=65)
Number of subjects: 130
Study 21815451 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of stent‐related symptoms
Number of subjects: 130
Study 19216779 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17974032 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate (1500 mg/day)
Number of subjects: 95
Study 17974032 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparagen (1800 mg/day)
Number of subjects: 95
Study 15162947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose phenobarbital therapy (40 mg/kg during the first 60 min after birth)
Number of subjects: 73
Study 15162947 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of phenobarbital (only if clinical evidence of seizures)
Number of subjects: 73
Study 11220254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 microg/kg)
Number of subjects: 44
Study 11220254 — intervention group
Group type: COMPARATOR
Intervention: Esmolol (2 mg/kg)
Number of subjects: 44
Study 9389827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/d)
Number of subjects: 28
Study 9389827 — intervention group
Group type: COMPARATOR
Intervention: Standard hormone replacement without aspirin (Control)
Number of subjects: 28
Study 7894214 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte alpha-interferon cream (2 x 10(6) IU/g) applied thrice a day for 3 consecutive days (group A) or 4 consecutive days (group B) per week, for a maximum of 4 weeks.
Number of subjects: 150
Study 7894214 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied in the same manner as the active treatment.
Number of subjects: 150
Study 3120436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg nitroglycerin
Number of subjects: 40
Study 3120436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Number of subjects: 0
Study 28957728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg) in participants with greater nicotine dependence
Number of subjects: 0
Study 28957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine on Day 1 or Placebo on Day 2
Number of subjects: 0
Study 28957728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine on Day 2
Number of subjects: 0
Study 27587328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 19114
Study 27587328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study 24042066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine clonixinate plus tramadol (LC 125 mg + T 25 mg)
Number of subjects: 40
Study 24042066 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (T) alone (50 mg)
Number of subjects: 40
Study 22738270 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling at TE5
Number of subjects: 43
Study 22738270 — intervention group
Group type: COMPARATOR
Intervention: Sham needling at TE5
Number of subjects: 43
Study 22738270 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling/sham needling at TE5
Number of subjects: 43
Study 22738270 — intervention group
Group type: COMPARATOR
Intervention: Sham needling at the sham point
Number of subjects: 43
Study 22738270 — intervention group
Group type: COMPARATOR
Intervention: Needling at the sham point
Number of subjects: 43
Study 21034646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery perfusion with hypothermic HTK solution
Number of subjects: 24
Study 21034646 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pulmonary artery perfusion)
Number of subjects: 24
Study 17482611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination for 6 months
Number of subjects: 51
Study 17482611 — intervention group
Group type: COMPARATOR
Intervention: Expectant management for 6 months
Number of subjects: 51
Study 15755850 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d) for 6 months in SGA-PP girls
Number of subjects: 62
Study 15755850 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH, 60 mug/kg/d) in SGA-SS children
Number of subjects: 62
Study 15755850 — intervention group
Group type: COMPARATOR
Intervention: Untreated SGA-PP girls
Number of subjects: 62
Study 15755850 — intervention group
Group type: COMPARATOR
Intervention: Untreated SGA-SS children
Number of subjects: 62
Study 11916785 — intervention group
Group type: EXPERIMENTAL
Intervention: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000) and a sham IV injection of 2 mL of saline solution
Number of subjects: 40
Study 11916785 — intervention group
Group type: EXPERIMENTAL
Intervention: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000)
Number of subjects: 40
Study 11916785 — intervention group
Group type: COMPARATOR
Intervention: IV morphine sulfate (0.1 mg/kg diluted to 2 mL)
Number of subjects: 40
Study 8682014 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily for 2 weeks, then 200 mg daily for 2 years
Number of subjects: 967
Study 8682014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 967
Study 8682014 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 967
Study 2676908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (initial dose 800 mg, additional 400 mg as needed)
Number of subjects: 40
Study 2676908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 322082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (1.2 to 2.4 mg/kg/day)
Number of subjects: 18
Study 322082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30590353 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to the rectus femoris and gastrocnemius muscles
Number of subjects: 49
Study 30590353 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 49
Study 27629275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher volumes of plasma expansion (crystalloid and colloid)
Number of subjects: 841
Study 26044353 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 193